Fig. 4From: Knowledge, experiences, and attitudes of Australian General Practitioners towards medicinal cannabis: a 2021–2022 surveyConcerns around the safety and efficacy of THC products (Panel A, n=505).Concerns around the safety and efficacy of CBD products (Panel B, n=505). Numbers show percentage of GPs (n=505) endorsing agreement, disagreement, and neutrality around specific concernsBack to article page